FGFR3 and gastric neoplasm: FGFR3 fusions were characteristic of bladder/urinary tract cancer (1.8%), central nervous system/brain tumors (1.2%), cervical cancer (0.6%), kidney cancer (0.4%), and esophagogastric/stomach cancer (0.4%).